To further determine whether this combination strategy can suppress the aggressive properties of stem cell-like tumor subpopulations responsible for tumor recurrence, the effect of Spautin-1 and 2-DG combination treatment on stemness of CD133/PROM1HIGH patient-derived GBM cells was assessed. This evidence concerns the gene PROM1 and glioblastoma.